MedTrace Logo

24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease

NCT02579252 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 208

Last updated 2019-11-14

No results posted yet for this study

Summary

This study evaluates the safety and efficacy of AADvac1 in the treatment of patients with mild Alzheimer's disease.

60% of participants will receive AADvac1 and 40% of participants will receive placebo.

Conditions

Interventions

BIOLOGICAL

AADvac1

DRUG

Placebo

Sponsors & Collaborators

  • Axon Neuroscience SE

    lead INDUSTRY

Principal Investigators

  • Reinhold Schmidt, Prof. MD. · Medical University, Graz, Austria

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2019-06-30
Completion
2019-06-30

Countries

  • Austria
  • Czechia
  • Germany
  • Poland
  • Romania
  • Slovakia
  • Slovenia
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02579252 on ClinicalTrials.gov